In the treatment setting, PCSK9 inhibitor antibodies may find a useful place as part of the existing guideline recommendations for the treatment of hypercholesterolemia in patients with or without clinical ASCVD needing additional LDL-C reductions despite statin regimens. This evidence concerns the gene PCSK9 and Hypercholesterolemia.